Download our whitepaper,

Psoriasis Clinical Trials: PASI Scores
and Beyond

What's Inside:

  • PASI scoring methodology and inter-rater reliability.
  • Biologic therapy development for moderate-to-severe psoriasis.
  • Quality of life instruments (DLQI) in dermatology trials.
  • Photographic documentation and centralized reading.
  • Long-term safety monitoring for immunosuppressive therapies.
  • Patient-reported outcomes in psoriasis management.

Access your complimentary whitepaper today:






    Melanoma

    Melanoma is a form of skin cancer that primarily develops from melanocytes, the cells responsible for producing pigment in the skin.

    It often begins as a change in an existing mole or the appearance of a new, unusual growth on the skin.

    This advanced understanding has led to the creation of therapies that not only target the visible symptoms but also address the underlying biological mechanisms of the disease.

    iNGENū’s team of experienced researchers and clinicians is dedicated to advancing melanoma research. Through innovative trial designs and patient-focused strategies, we are committed to accelerating the development of new treatments that can improve the lives of those affected by melanoma.

    65%

    of melanomas develop on parts of the body that receive little sun exposure

    Melanoma diagnoses grew

    3x

    in the last 40 years in the USA

    75%

    of skin cancer deaths are caused by melanoma

    Our clinical team has over

    120

    years of combined clinical trial experience